299 related articles for article (PubMed ID: 7595735)
1. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
[TBL] [Abstract][Full Text] [Related]
2. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
4. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
Lise M; Nitti D; Marchet A; Sahmoud T; Duez N; Fornasiero A; dos Santos JG; Labianca R; Lasser P; Gignoux M
Ann Surg Oncol; 1995 Nov; 2(6):495-501. PubMed ID: 8591079
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Macdonald JS; Fleming TR; Peterson RF; Berenberg JL; McClure S; Chapman RA; Eyre HJ; Solanki D; Cruz AB; Gagliano R
Ann Surg Oncol; 1995 Nov; 2(6):488-94. PubMed ID: 8591078
[TBL] [Abstract][Full Text] [Related]
8. Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
Lise M; Nitti D; Buyse M; Cartei G; Fornasiero A; Guimaraes dos Santos J; Duez N
Recent Results Cancer Res; 1988; 110():36-43. PubMed ID: 3043595
[No Abstract] [Full Text] [Related]
9. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
Coombes RC; Schein PS; Chilvers CE; Wils J; Beretta G; Bliss JM; Rutten A; Amadori D; Cortes-Funes H; Villar-Grimalt A
J Clin Oncol; 1990 Aug; 8(8):1362-9. PubMed ID: 2199622
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant FAM2 in resectable gastric cancer.
Lise M; Nitti D; Buyse M; Marchet A; Fiorentino M; Dos Santos JG; Duez N
Anticancer Res; 1989; 9(4):1017-21. PubMed ID: 2683987
[TBL] [Abstract][Full Text] [Related]
12. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
13. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
[TBL] [Abstract][Full Text] [Related]
14. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
[TBL] [Abstract][Full Text] [Related]
16. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Popiela T; Kulig J; Czupryna A; Szczepanik AM; Zembala M
Gastric Cancer; 2004; 7(4):240-5. PubMed ID: 15616772
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Jeung HC; Moon YW; Rha SY; Yoo NC; Roh JK; Noh SH; Min JS; Kim BS; Chung HC
Ann Oncol; 2008 Mar; 19(3):520-6. PubMed ID: 18029971
[TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi JH; Lim HY; Joo HJ; Kim HS; Yi JW; Kim HC; Cho YK; Kim MW; Lee KB
Br J Cancer; 2002 May; 86(10):1578-85. PubMed ID: 12085207
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
Nitti D; Wils J; Dos Santos JG; Fountzilas G; Conte PF; Sava C; Tres A; Coombes RC; Crivellari D; Marchet A; Sanchez E; Bliss JM; Homewood J; Couvreur ML; Hall E; Baron B; Woods E; Emson M; Van Cutsem E; Lise M; ;
Ann Oncol; 2006 Feb; 17(2):262-9. PubMed ID: 16293676
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group.
Nakajima T; Nashimoto A; Kitamura M; Kito T; Iwanaga T; Okabayashi K; Goto M
Lancet; 1999 Jul; 354(9175):273-7. PubMed ID: 10440302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
